The most comprehensive
product portfolio
  • Dry Eye Disease
  • wAMD
  • Diabetic Macular Edema
  • Myopia
  • Glaucoma

Zhaoke is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. Leveraging our deep domain expertise, we have built a comprehensive ophthalmic drug pipeline of 25 candidates that covers most major ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing, including on five major ophthalmic indications in China :dry eye disease, or DED, wet age-related macular degeneration, or wAMD, diabetic macular edema, or DME, myopia and glaucoma.

We have built an ophthalmic drug pipeline comprising 13 innovative drugs, including 8 drug candidates which have the potential to be market-leading products in China if approved.
See innovative drugs
We have built an ophthalmic drug pipeline comprising 12 generic drugs.

Our generic pipeline includes 6 potential first-to-market generics in China

which we believe will bring us near-term cash flows and significant first-mover advantages in commercial-scale manufacturing and marketing.
see generic drugs
Allergic conjunctivitis
Corneal Epithelial Defects
Dry Eye Disease
Uveitis
Myopia
Diabetic Macular Edema
wAMD
Anti-infectives
& anti-inflammatory,
Diagnostic and Surgical use
VMT
Pterygium
Allergic conjunctivitis
Glaucoma
Anti-infectives
& anti-inflammatory,
Diagnostic and Surgical use